Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$5.83 USD
+0.03 (0.52%)
Updated May 31, 2024 04:00 PM ET
After-Market: $5.87 +0.04 (0.69%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Foghorn Therapeutics Inc. [FHTX]
Reports for Purchase
Showing records 21 - 40 ( 77 total )
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
FHD-286 Comes Out of FDA?s Penalty Box-Reflections on FHD-286?s New Combination Pathway in AML
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
FDA Lifts Clinical Hold; Clear Evidence of Activity, and Moving Forward
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q1 Financials; Readying for FHD-286 Clinical Updates in 2Q:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Unlocking The BAF Opportunity Requires Further Patience; Reit. Buy and Lowering Our PT to $20 from $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Clinical Hold For FHD-609, Does Not Deter Our Positive BAF Targeting Thesis
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
FHD-609 Program on Pause; Reducing PT to $15 (from $20)
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Biotechnology- Roundup for 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Remain Bullish Ahead of FHD-286 Data in 1H23; Reit. Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q4 Financials; Line of Sight to Key Readouts in 2023
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
SITC 2022 Conference Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Mechanistic rationale of FHD-286, Ahead of Initial 1H23 Data Leaves Us Bullish; Reit. Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Foghorn Showcase Degraders Capability and New CBP Program at TPD Summit; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A